Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Apixaban on tunneled-cuffed hemodialysis catheter patency
IRCT20240228061124N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of apixaban in end-stage kidney disease (ESKD) and catheter-related thrombosis (CRT), sponsored by Urmia University of Medical Sciences. Started Mar 2024; status: completed.
02
Drugs
apixaban
03
Conditions
end-stage kidney disease (ESKD)catheter-related thrombosis (CRT)
Beyond the preview
Go deeper on IRCT20240228061124N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240228061124N1.